(redirected from Progression Free Survival)
Category filter:
PFSProgression Free Survival
PFSPhysician Fee Schedule (healthcare)
PFSPersonal Financial Specialist
PFSPerfect Forward Secrecy
PFSPartnerships for Schools (UK; public-private partnership)
PFSPersonal Financial Statement
PFSPersonal Financial Service
PFSPlaying for Success (UK)
PFSPrimerica Financial Services
PFSPrefilled Syringe
PFSPatient Financial Services
PFSParents' Financial Statement (various schools)
PFSPersonal Finance Solutions (UK)
PFSProvident Financial Services, Inc. (Jersey City, NJ)
PFSPlanetary Fourier Spectrometer
PFSPlays for Sure
PFSPhysical File System
PFSProfessional File System
PFSPortable File System
PFSPegasus File System
PFSParticle Filter System
PFSPluggable File System
PFSPersistent File System
PFSPool File System
PFSPartial File Sharing
PFSPremium Forwarding Service
PFSPolitical Film Society (Los Angeles, CA)
PFSPreliminary Feasibility Study
PFSPrinceton Financial Systems (Princeton, NJ)
PFSParallel File System
PFSPlaysForSure (Microsoft audio)
PFSPrime Fund Solutions (various companies)
PFSPower Flow Systems, Inc.(Florida)
PFSPartnership for Sustainability (Denver, CO)
PFSPulmonary Function System
PFSPrivate Fuel Storage, LLC
PFSProject First Step (various locations)
PFSParticulate Filter System (various companies)
PFSPrimary Flight System (US NASA)
PFSPercent Full Scale (pressure unit)
PFSPenang Free School (Penang, Malaysia)
PFSPatello-Femoral Syndrome
PFSPetrol Filling Station
PFSPersonal File System
PFSPlasma Flood System
PFSPower Failure Signal
PFSProcess Flow Scheduling
PFSPersonal File Sharing (Macintosh networking)
PFSProgressive Forest Split
PFSPrinceton Friends School
PFSPage Format Selection (ITU-T)
PFSPush Fit Socket (piping)
PFSPrevious Function State (computer architecture)
PFSPollution Abatement System (PAS) Filtration System
PFSProportional Fair Sharing (algorithm)
PFSPrinciple for Safety
PFSPassenger Final Sales (Message)
PFSPrincipal for Safety
PFSPhiladelphia Flower Show, Inc.
PFSProportionally Fair Scheduler
PFSPulmonary Function Study
PFSPosition Fixing System
PFSProcess Flow Scheme
PFSPure False Sharing
PFSProduct Function Specification
PFSPrimary Fuel Source
PFSPeat Fired Station
PFSPrepare for Service
PFSPositron Fiber System
PFSProfile Selector CSCI
PFSPublications and Forms Stockroom
PFSPreprocessor Flight Software
PFSPower Feeder Stub (Lucent)
PFSPod Forward Section
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
In 2017 Hacisalihogluet al., followed through with a retrospective analysis of 41 anaplastic OD cases, 35 patients received standard radiotherapy whilst 26 patients then underwent additional chemotherapy with temozolomide.2 In the 19 patients who had chromosomal 1p/19 co-deletion, progression free survival was noted to be significantly higher, regardless of treatment modality.
Advanced pancreatic cancer patients treated with Tumor Treating Fields plus gemcitabine experienced a median progression free survival of 8.3 months (95% CI 4.3, 10.3) and a median overall survival of 14.9 months (95% CI 6.2, NA), compared to 3.7 months and 6.7 months, respectively, in the gemcitabine historical control.
Median progression free survival in the Tumor Treating Fields-treated group was 8.9 months (compared to 3.9 months in paclitaxel-alone historical controls) and median overall survival was not yet reached.
Around 495 patients have participated in the trial, whose primary endpoint is Progression Free Survival, while secondary endpoints include overall survival, objective response rate, duration of response and other safety, pharmacokinetic and quality of life measures.
At the Society for Immunotherapy of Cancer 33rd Annual Meeting, Leap announced that the combination of DKN-01 and paclitaxel generated a 46.7% overall response rate, 19.6 weeks median progression free survival, and 61.1 weeks median overall survival in fifteen evaluable esophagogastric cancer patients as a second-line therapy.
The trial will be carried out in around 150 sites in North America, Europe and Asia-Pacific, with its co-primary endpoints being progression free survival and overall survival.
The primary outcome measures are tumor response rate and determination of maximum tolerated dose, while the secondary outcome measures include progression free survival, overall survival, duration of response and pharmacokinetics.
The co-primary endpoints of the trial are progression free survival and overall survival.